Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Rowe

Showing results (111-120 of 269) with videos related to

Pageof 27
Sort By:
International Forum of Allergy & Rhinology|October 27, 2021
Ivacaftor restores delayed mucociliary transport caused by Pseudomonas aeruginosa-induced acquired cystic fibrosis transmembrane conductance regulator dysfunction in rabbit nasal epitheliaDo-Yeon Cho, Shaoyan Zhang, Daniel F Skinner, et al.
Chest|June 25, 2008
Genetic and reproductive knowledge among adolescents and adults with cystic fibrosisGrace H Houser, Cheryl L Holt, J P Clancy, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 27, 2025
Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutationsKari Thrasher, Jianguo Chen, Lianwu Fu, et al.
Research Square|June 10, 2024
Reduced Sialylation of Airway Mucin Impairs Mucus Transport by Altering the Biophysical Properties of MucinElex S Harris, Hannah J McIntire, Marina Mazur, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 4, 2023
The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulatorsJianguo Chen, Kari Thrasher, Lianwu Fu, et al.
The Lancet. Respiratory Medicine|June 29, 2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael P Boyle, Scott C Bell, Michael W Konstan, et al.
Chest|February 16, 2013
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosisSteven M Rowe, Ginger Reeves, Heather Hathorne, et al.
International Forum of Allergy & Rhinology|August 21, 2019
Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesiaJustin P McCormick, Christopher G Weeks, Nicholas J Rivers, et al.
Fertility and Sterility|January 27, 2010
Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferensViktoria Havasi, Steven M Rowe, Peter N Kolettis, et al.
Respiratory Research|October 10, 2022
Comparative transcriptomics in human COPD reveals dysregulated genes uniquely expressed in ferretsShah S Hussain, Yvonne J K Edwards, Emily Falk Libby, et al.
Pageof 27

Showing results (111-120 of 269) with videos related to

Sort By:
Pageof 27
International Forum of Allergy & Rhinology|October 27, 2021
Ivacaftor restores delayed mucociliary transport caused by Pseudomonas aeruginosa-induced acquired cystic fibrosis transmembrane conductance regulator dysfunction in rabbit nasal epitheliaDo-Yeon Cho, Shaoyan Zhang, Daniel F Skinner, et al.
Chest|June 25, 2008
Genetic and reproductive knowledge among adolescents and adults with cystic fibrosisGrace H Houser, Cheryl L Holt, J P Clancy, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 27, 2025
Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutationsKari Thrasher, Jianguo Chen, Lianwu Fu, et al.
Research Square|June 10, 2024
Reduced Sialylation of Airway Mucin Impairs Mucus Transport by Altering the Biophysical Properties of MucinElex S Harris, Hannah J McIntire, Marina Mazur, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 4, 2023
The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulatorsJianguo Chen, Kari Thrasher, Lianwu Fu, et al.
The Lancet. Respiratory Medicine|June 29, 2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael P Boyle, Scott C Bell, Michael W Konstan, et al.
Chest|February 16, 2013
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosisSteven M Rowe, Ginger Reeves, Heather Hathorne, et al.
International Forum of Allergy & Rhinology|August 21, 2019
Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesiaJustin P McCormick, Christopher G Weeks, Nicholas J Rivers, et al.
Fertility and Sterility|January 27, 2010
Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferensViktoria Havasi, Steven M Rowe, Peter N Kolettis, et al.
Respiratory Research|October 10, 2022
Comparative transcriptomics in human COPD reveals dysregulated genes uniquely expressed in ferretsShah S Hussain, Yvonne J K Edwards, Emily Falk Libby, et al.
Pageof 27